|
May 2
|
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
|
|
Apr 30
|
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
|
|
Apr 18
|
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
|
|
Apr 4
|
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
|
|
Apr 1
|
Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans?
|
|
Mar 8
|
Arbutus to Participate in Two Upcoming Investor Conferences
|
|
Feb 29
|
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
|
|
Feb 29
|
Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials
|
|
Feb 29
|
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
|
|
Jan 1
|
Institutions own 30% of Arbutus Biopharma Corporation (NASDAQ:ABUS) shares but individual investors control 32% of the company
|
|
Nov 8
|
Arbutus to Present at Jefferies London Healthcare Conference
|
|
Nov 8
|
Q3 2023 Arbutus Biopharma Corp Earnings Call
|
|
Nov 7
|
Arbutus Biopharma Corp (ABUS) Reports Q3 2023 Financial Results
|
|
Nov 7
|
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
|
|
Nov 7
|
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
|
|
Aug 26
|
Arbutus Biopharma (NASDAQ:ABUS) shareholders have endured a 78% loss from investing in the stock five years ago
|